Combined Shareholders’ Meeting of 30 May 2018
Combined Shareholders’ Meeting of 30 May 2018
Paris (France), 9 May 2018 – The Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 30 May 2018 at 3 pm (Paris time) at the Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d’Iéna, 75116 Paris, France.
The preliminary notice of meeting was published in the Bulletin des Annonces Légales Obligatoires (BALO) of 20 April 2018 and the notice of meeting in the BALO of 9 May 2018. These documents, as well as the Convening notice (including, in particular, the agenda, the proposed resolutions and the conditions regarding attendance and vote), are also available on Ipsen’s website at the following address: www.ipsen.com, under the “Investors/Shareholders’ meetings” section.
Documents and information relating to this Meeting will be made available to shareholders under the legal and regulatory conditions in force.
In accordance with applicable regulatory provisions:
- Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (attestation de participation) in the bearer securities accounts managed by the authorized intermediary.
- Any shareholder may consult these documents at the Company’s headquarters.
Combined Shareholders’ Meeting of 30 May 2018
Paris (France), 9 May 2018 – The Shareholders of the Company are invited to participate in the Combined Shareholders’ Meeting of Ipsen (Euronext: IPN; ADR: IPSEY) to be held on Wednesday 30 May 2018 at 3 pm (Paris time) at the Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d’Iéna, 75116 Paris, France.
The preliminary notice of meeting was published in the Bulletin des Annonces Légales Obligatoires (BALO) of 20 April 2018 and the notice of meeting in the BALO of 9 May 2018. These documents, as well as the Convening notice (including, in particular, the agenda, the proposed resolutions and the conditions regarding attendance and vote), are also available on Ipsen’s website at the following address: www.ipsen.com, under the “Investors/Shareholders’ meetings” section.
Documents and information relating to this Meeting will be made available to shareholders under the legal and regulatory conditions in force.
In accordance with applicable regulatory provisions:
- Registered shareholders may, up to the fifth day (inclusive) before the Meeting, request from the Company to send these documents, where appropriate at his/her express request by electronic means. For holders of bearer shares, the exercise of this right is subject to the presentation of a shareholding certificate (attestation de participation) in the bearer securities accounts managed by the authorized intermediary.
- Any shareholder may consult these documents at the Company’s headquarters.
Related Documents
-
Availability and consultation of preparatory documentation for the Shareholders' Meeting 2018
(287 KB)
-
Board Report to ASM 2018
(277 KB)
-
Convening notice 2018
(2 MB)
-
Notice of meeting 2018
(140 KB)
-
Prior notice to the Meeting 2018
(395 KB)
-
Universal registration document 2017
(5 MB)
-
Voting form
(2 MB)
-
Voting results
(170 KB)
Related Press Releases
![Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
![Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan
![Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023
![Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023 Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023
![Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
![Combined Shareholders’ Meeting of 24 May 2022 Combined Shareholders’ Meeting of 24 May 2022](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
Combined Shareholders’ Meeting of 24 May 2022
![Combined Shareholders’ Meeting of 7 June 2017 Combined Shareholders’ Meeting of 7 June 2017](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)